REDUCER I
OBSERVATIONAL STUDY

CORONARY SINUS REDUCER FOR TREATMENT OF REFRACTORY ANGINA IN PATIENTS WITH NON-OBSTRUCTIVE CORONARY DISEASE[1]

REDUCER I is a prospective, open-label, multi-center, international, post-market study which collects long-term data of patients with refractory angina treated with the Shockwave™ Reducer.

NON-OBSTRUCTIVE CAD SUB-ANALYSIS RESULTS

REDUCER I patients with non-obstructive coronary artery disease (CAD) receiving a Reducer device achieved a statistically significant improvement in Quality of Life (QoL) and an improvement in CCS class at 12 months.

Non-Obstructive CAD defined as less than 70% stenosis by visual estimate in all major epicardial coronary arteries.

Seattle Angina Questionnaire

Both cohorts had significant improvements in QoL measures at 12 months.





Canadian Cardiovascular Class

Both Obstructive CAD and Non-Obstructive CAD cohorts had improved CCS class at 12 months with no significant differences (p=0.1178) between the groups.

Obstructive CAD

71.7% (162/226) with ≥1 CCS class improvement



Non-Obstructive CAD

60.3% (35/58) with ≥1 CCS class improvement



KEY TAKEAWAYS FROM THE REDUCER I NON-OBSTRUCTIVE DISEASE DATA

- Patients with refractory angina can include those with revascularized non-obstructive CAD and treatments are needed for this important patient population
- Implant of the Reducer device resulted in significant symptomatic improvements in anginal severity (p=0.0003) and quality of life (p=0.0002)
- RCTs examining the efficacy of the CSR in patients with ANOCA (both with and without a history of prior CAD) are ongoing (REMEDY-PILOT and REDUCE CMD)

CREATING BETTER OUTCOMES WITH MOUNTING CLINICAL EVIDENCE

REDUCER I OBSERVATIONAL STUDY | COSIRA II

Scan to Learn More

LIMITATIONS
This is a hypothesis-generating sub-analysis of the Reducer I registry. The registry is limited in its documentation of ischaemia testing and baseline medications.

FOOTNOTES
1. de Silva, R. 2025, Coronary Sinus Reducer for Treatment of Refractory Angina in Patients with Non-Obstructive Coronary Disease, PCR, 2025, May 22, Paris

CAUTION In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use. The Reducer is subject of Investigational testing and is being studied in the COSIRA-II trial in Canada. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability. Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events: ifu.sw-reducer.com

SHOCKWAVE REDUCER

Johnson&Johnson MedTech

SHOCKWAVE MEDICAL